Client Result
Orrick Advises Third Rock Ventures on Investment in CARGO Therapeutics
1 minute read | March.02.2023
The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022.
1 minute read | March.02.2023
The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022.
September.19.2022
September.10.2021
Orrick advised Sprints Capital on its investment in relationship intelligence platform Affinity’s $80 million Series C financing round.
June.25.2021
We have advised lead investor Third Rock Ventures, as well as Lightspeed Venture Partners, on their investment in Abata Therapeutics’ Series A round.
June.04.2020